​

​

​

​

​

 

​​A strategic ally to amplify your competitive intelligence (CI) capabilities.

​​

Benchmark Your Data Across the Entire Industry

Give your CI team the objective context they can't get in-house

​​​

    Analyze 3,400+ companies and 7,700+ assets across 35 clinical and commercial metrics

    Quantify addressable patient populations across every cancer type, line of therapy, and biomarker

    Link drug safety outcomes to commercial impact by benchmarking dose modifications, discontinuations, and        fatal adverse events (AEs) across all approved therapies

​​​

Make decisions with real industry baselines, not isolated competitor anecdotes

​​​

Move Beyond Conference Monitoring

Spot threats and opportunities before anyone's presenting them

​​

    Detect emerging companies, platforms, and assets before they appear on conference floors

    Track pipeline shifts before press releases, abstracts, or posters are released

    Accelerate BD diligence by surfacing next-generation technologies ahead of market buzz

​​

Engage breakout biotech companies before they make headlines

​

Harness the Evolving Patient Landscape

Build a strategy that unites patient impact with portfolio performance

​​

    Quantify addressable markets using clinically-relevant patient status and biomarker data across all cancers

    Model the therapeutic benchmarks needed to be a standout in earlier lines of therapy

    Analyze treatment option density to find white space and treat high unmet need populations

​​

Pinpoint patient needs and position your portfolio to lead the next standard of care